Gilead's (GILD) HCV Drug Harvoni's Label Expanded in U.S.

Gilead Sciences, Inc. GILD announced a label expansion for its hepatitis C virus (HCV) infection drug, Harvoni, in the U.S. With the label expansion, Harvoni can now be used for the treatment of patients with chronic HCV genotypes 4, 5 and 6 infection and in patients co-infected with HIV. Additionally, Harvoni, in combination with ribavirin as a 12-week...